Titre : Complexe répresseur Polycomb-1

Complexe répresseur Polycomb-1 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Recovery of Function
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Complexe répresseur Polycomb-1 : Questions médicales les plus fréquentes", "headline": "Complexe répresseur Polycomb-1 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Complexe répresseur Polycomb-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-16", "dateModified": "2025-03-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Complexe répresseur Polycomb-1" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines du groupe Polycomb", "url": "https://questionsmedicales.fr/mesh/D063146", "about": { "@type": "MedicalCondition", "name": "Protéines du groupe Polycomb", "code": { "@type": "MedicalCode", "code": "D063146", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.930.780.890" } } }, "about": { "@type": "MedicalCondition", "name": "Complexe répresseur Polycomb-1", "alternateName": "Polycomb Repressive Complex 1", "code": { "@type": "MedicalCode", "code": "D063150", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Haruhiko Koseki", "url": "https://questionsmedicales.fr/author/Haruhiko%20Koseki", "affiliation": { "@type": "Organization", "name": "Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences (RIKEN-IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan; AMED-CREST, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan." } }, { "@type": "Person", "name": "Atsushi Iwama", "url": "https://questionsmedicales.fr/author/Atsushi%20Iwama", "affiliation": { "@type": "Organization", "name": "Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo, Japan." } }, { "@type": "Person", "name": "Elena Ezhkova", "url": "https://questionsmedicales.fr/author/Elena%20Ezhkova", "affiliation": { "@type": "Organization", "name": "Black Family Stem Cell Institute, The Tisch Cancer Institute, Department of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA. Electronic address: elena.ezhkova@mssm.edu." } }, { "@type": "Person", "name": "Claudia Köhler", "url": "https://questionsmedicales.fr/author/Claudia%20K%C3%B6hler", "affiliation": { "@type": "Organization", "name": "Department of Plant Biology, Swedish University of Agricultural Sciences and Linnean Center for Plant Biology, 75007, Uppsala, Sweden. koehler@mpimp-golm.mpg.de." } }, { "@type": "Person", "name": "Lars Hennig", "url": "https://questionsmedicales.fr/author/Lars%20Hennig", "affiliation": { "@type": "Organization", "name": "Department of Plant Biology, Swedish University of Agricultural Sciences and Linnean Center for Plant Biology, 75007, Uppsala, Sweden." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "\"Being here is saving my life\": Resident experiences of living in recovery residences for people taking medication for an opioid use disorder.", "datePublished": "2023-12-06", "url": "https://questionsmedicales.fr/article/38061632", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.josat.2023.209242" } }, { "@type": "ScholarlyArticle", "name": "Prognostic Factors for Recovery from Left Recurrent Laryngeal Nerve Palsy After Minimally Invasive McKeown Esophagectomy: A Retrospective Study.", "datePublished": "2023-11-21", "url": "https://questionsmedicales.fr/article/37989958", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1245/s10434-023-14560-7" } }, { "@type": "ScholarlyArticle", "name": "What do we not know (yet) about recovery colleges? A study protocol on their (cost-)effectiveness, mechanisms of action, fidelity and positioning.", "datePublished": "2023-11-08", "url": "https://questionsmedicales.fr/article/37940915", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12888-023-05293-8" } }, { "@type": "ScholarlyArticle", "name": "The effect of a night shift nap on post-night shift performance, sleepiness, mood, and first recovery sleep: A randomized crossover trial.", "datePublished": "2023-11-07", "url": "https://questionsmedicales.fr/article/37933729", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5271/sjweh.4129" } }, { "@type": "ScholarlyArticle", "name": "Valorization and co-treatment of hazardous petroleum refinery oily sludge and sewage associated with bioenergy recovery in tubular microbial fuel cell.", "datePublished": "2023-11-04", "url": "https://questionsmedicales.fr/article/37924404", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11356-023-30773-5" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Facteurs de transcription", "item": "https://questionsmedicales.fr/mesh/D014157" }, { "@type": "ListItem", "position": 5, "name": "Protéines de répression", "item": "https://questionsmedicales.fr/mesh/D012097" }, { "@type": "ListItem", "position": 6, "name": "Protéines du groupe Polycomb", "item": "https://questionsmedicales.fr/mesh/D063146" }, { "@type": "ListItem", "position": 7, "name": "Complexe répresseur Polycomb-1", "item": "https://questionsmedicales.fr/mesh/D063150" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Complexe répresseur Polycomb-1 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Complexe répresseur Polycomb-1", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Complexe répresseur Polycomb-1", "description": "Comment diagnostiquer une dysfonction du PRC1 ?\nQuels tests sont utilisés pour évaluer le PRC1 ?\nLe diagnostic nécessite-t-il une biopsie ?\nQuels marqueurs sont associés au PRC1 ?\nLe diagnostic est-il basé sur des symptômes cliniques ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Recovery+of+Function&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Complexe répresseur Polycomb-1", "description": "Quels symptômes indiquent une anomalie du PRC1 ?\nLe PRC1 est-il lié à des cancers spécifiques ?\nLes troubles neurologiques sont-ils liés au PRC1 ?\nLe PRC1 affecte-t-il le métabolisme ?\nY a-t-il des symptômes généraux associés au PRC1 ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Recovery+of+Function&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Complexe répresseur Polycomb-1", "description": "Peut-on prévenir les anomalies liées au PRC1 ?\nY a-t-il des tests de dépistage pour le PRC1 ?\nLes antécédents familiaux influencent-ils le risque ?\nDes conseils génétiques sont-ils disponibles ?\nL'alimentation joue-t-elle un rôle dans la prévention ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Recovery+of+Function&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Complexe répresseur Polycomb-1", "description": "Quels traitements ciblent le PRC1 ?\nLa chimiothérapie est-elle efficace contre les anomalies du PRC1 ?\nDes traitements expérimentaux existent-ils pour le PRC1 ?\nLe PRC1 peut-il être ciblé par des médicaments spécifiques ?\nLes thérapies combinées sont-elles efficaces pour le PRC1 ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Recovery+of+Function&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Complexe répresseur Polycomb-1", "description": "Quelles complications peuvent survenir avec le PRC1 ?\nLe PRC1 est-il lié à des maladies auto-immunes ?\nLes complications sont-elles réversibles ?\nLe PRC1 affecte-t-il la qualité de vie ?\nY a-t-il des complications neurologiques associées ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Recovery+of+Function&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Complexe répresseur Polycomb-1", "description": "Quels sont les facteurs de risque pour le PRC1 ?\nL'âge est-il un facteur de risque pour le PRC1 ?\nLes facteurs environnementaux influencent-ils le PRC1 ?\nLe sexe joue-t-il un rôle dans le risque de PRC1 ?\nLe mode de vie influence-t-il le risque de PRC1 ?", "url": "https://questionsmedicales.fr/mesh/D063150?mesh_terms=Recovery+of+Function&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction du PRC1 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des analyses génétiques et des études d'expression génique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer le PRC1 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de séquençage et des analyses de chromatine sont couramment utilisés." } }, { "@type": "Question", "name": "Le diagnostic nécessite-t-il une biopsie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une biopsie peut être nécessaire pour analyser les tissus affectés par le PRC1." } }, { "@type": "Question", "name": "Quels marqueurs sont associés au PRC1 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs épigénétiques comme les modifications des histones sont souvent analysés." } }, { "@type": "Question", "name": "Le diagnostic est-il basé sur des symptômes cliniques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes cliniques peuvent orienter le diagnostic, mais des tests spécifiques sont nécessaires." } }, { "@type": "Question", "name": "Quels symptômes indiquent une anomalie du PRC1 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies de développement et des troubles de la différenciation cellulaire peuvent survenir." } }, { "@type": "Question", "name": "Le PRC1 est-il lié à des cancers spécifiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations dans le PRC1 sont associées à divers types de cancers, notamment le cancer du sein." } }, { "@type": "Question", "name": "Les troubles neurologiques sont-ils liés au PRC1 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent un lien entre le PRC1 et des troubles neurologiques, mais les recherches sont en cours." } }, { "@type": "Question", "name": "Le PRC1 affecte-t-il le métabolisme ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches indiquent que le PRC1 peut influencer le métabolisme cellulaire et énergétique." } }, { "@type": "Question", "name": "Y a-t-il des symptômes généraux associés au PRC1 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue et des anomalies de croissance peuvent être observés." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies liées au PRC1 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut réduire certains risques." } }, { "@type": "Question", "name": "Y a-t-il des tests de dépistage pour le PRC1 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de tests de dépistage standardisés pour les anomalies du PRC1." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancers peuvent augmenter le risque d'anomalies du PRC1." } }, { "@type": "Question", "name": "Des conseils génétiques sont-ils disponibles ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des conseils génétiques peuvent aider à évaluer le risque et à discuter des options de prévention." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut contribuer à la santé cellulaire, mais ne prévient pas spécifiquement les anomalies du PRC1." } }, { "@type": "Question", "name": "Quels traitements ciblent le PRC1 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs de la méthylation des histones et des thérapies géniques sont explorés." } }, { "@type": "Question", "name": "La chimiothérapie est-elle efficace contre les anomalies du PRC1 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La chimiothérapie peut être utilisée, mais son efficacité dépend du type de cancer associé." } }, { "@type": "Question", "name": "Des traitements expérimentaux existent-ils pour le PRC1 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements expérimentaux sont en cours d'évaluation dans des essais cliniques." } }, { "@type": "Question", "name": "Le PRC1 peut-il être ciblé par des médicaments spécifiques ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours pour développer des médicaments ciblant spécifiquement le PRC1." } }, { "@type": "Question", "name": "Les thérapies combinées sont-elles efficaces pour le PRC1 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies combinées peuvent améliorer l'efficacité des traitements contre les cancers liés au PRC1." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le PRC1 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des cancers avancés et des troubles de développement sévères." } }, { "@type": "Question", "name": "Le PRC1 est-il lié à des maladies auto-immunes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien potentiel entre le PRC1 et certaines maladies auto-immunes." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Le PRC1 affecte-t-il la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les anomalies du PRC1 peuvent significativement affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Y a-t-il des complications neurologiques associées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines anomalies du PRC1 peuvent entraîner des complications neurologiques, comme des troubles cognitifs." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour le PRC1 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des mutations génétiques, des antécédents familiaux et des expositions environnementales." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour le PRC1 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains types de cancers liés au PRC1 sont plus fréquents chez les personnes âgées." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils le PRC1 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des expositions à des agents cancérigènes peuvent augmenter le risque d'anomalies du PRC1." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans le risque de PRC1 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains cancers liés au PRC1 montrent des différences de prévalence entre les sexes." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque de PRC1 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie malsain, comme le tabagisme, peut augmenter le risque d'anomalies du PRC1." } } ] } ] }

Sources (10000 au total)

"Being here is saving my life": Resident experiences of living in recovery residences for people taking medication for an opioid use disorder.

Medications for opioid use disorder (MOUD) are an effective treatment for addressing opioid use disorder. Despite MOUD's demonstrated effectiveness, MOUD-related stigma is prevalent throughout many re... We conducted in-depth interviews with 47 residents in medication-assisted recovery (MAR) living in 11 Texas-based recovery residences serving people taking MOUD to characterize residents' experiences ... We found that many participants could not previously access recovery housing and other recovery supports due to MOUD-related stigma, thus recovery homes that supported people in MAR were considered a ... Recovery residences that serve people in MAR provide a supportive, safe, nonjudgmental recovery environment in which residents develop relationships with other peers taking MOUD, share openly about th...

Prognostic Factors for Recovery from Left Recurrent Laryngeal Nerve Palsy After Minimally Invasive McKeown Esophagectomy: A Retrospective Study.

Recurrent laryngeal nerve (RLN) palsy is a serious complication of esophagectomy that affects the patient's phonation and the ability to prevent life-threatening aspiration events. The aim of this sin... The study cohort consisted of 85 patients who had developed left RLN palsy after minimally invasive McKeown esophagectomy. Vocal cord function was assessed in all participants through laryngoscopic ex... Twenty-two (25.8%) patients successfully recovered from left RLN palsy. On multivariable logistic regression analysis, active smoking (odds ratio [OR] 0.335, p = 0.038) and the use of thoracoscopic su... Only one-quarter of patients who had developed left RLN palsy after minimally invasive McKeown esophagectomy were able to fully recover. Smoking habits and the surgical approach were identified as key...

What do we not know (yet) about recovery colleges? A study protocol on their (cost-)effectiveness, mechanisms of action, fidelity and positioning.

Recovery Colleges (RCs) have spread across the globe as a new way of supporting people with mental vulnerabilities in their recovery journey. RCs focus on 'learning' rather than 'curing' and in that l... This research project entails (1) a prospective quasi-experimental effectiveness study and economic evaluation, (2) a multifaceted qualitative study to elaborate on the mechanisms of action of RCs for... This research project will lead to one of the first longitudinal controlled quantitative evaluations of both cost-effectiveness and effectiveness of RC attendance in a broad sense (beyond attending co... The prospective quasi-experimental study has been pre-registered at clinicaltrails.gov (#NCT05620212)....

The effect of a night shift nap on post-night shift performance, sleepiness, mood, and first recovery sleep: A randomized crossover trial.

This study aimed to test the effect of a 30-minute nap versus a 2-hour nap opportunity taken during a simulated night shift on performance, fatigue, sleepiness, mood, and sleep at the end of shift and... We conducted a randomized crossover trial of three nap conditions (30-minute, 2-hour, and no-nap) during 12-hour simulated night shifts. We tested for differences in performance, fatigue, sleepiness, ... Twenty-eight individuals consented to participate [mean age 24.4 (standard deviation 7.2) years; 53.6% female; 85.7% Emergency Medical Services clinicians]. PVT-B false starts at the end of the 12-hou... A 2-hour nap opportunity versus a 30-minute or no-nap opportunity is beneficial for performance, alertness, and mood post-night shift. No differences were detected in sleep during recovery....

Enhanced recovery programme after colorectal surgery in high-income and low-middle income countries: a systematic review and meta-analysis.

Enhanced recovery after surgery (ERAS) protocols strive to optimise outcomes following elective surgery; however, there is a dearth of evidence to support its equitable application and efficacy intern... The authors performed a systematic review and meta-analysis of studies on the uptake and impact of ERAS with the aim of highlighting differences in implementation and outcomes across high-income count... Three hundred thirty-seven studies with considerable heterogeneity were included in the analysis (291 from HICs, and 46 from LMICs) with a total of 110 190 patients. The weighted median number of impl... Considerable variation in the structure, the implementation and outcomes of ERAS exists between HICs and LMICs, where affordable elements are implemented, contributing towards longer LOS in LMICs. Glo...

Standardized measurement of balance and mobility post-stroke: Consensus-based core recommendations from the third Stroke Recovery and Rehabilitation Roundtable.

Mobility is a key priority for stroke survivors. Worldwide consensus of standardized outcome instruments for measuring mobility recovery after stroke is an essential milestone to optimize the quality ... Using a standardized methodology, which involved convening of 13 worldwide experts in the field of mobility rehabilitation, consensus was established through an... Selected measures included the Fugl-Meyer Motor Assessment lower extremity subscale for motor function, the Trunk Impairment Scale for sitting balance, and the Mini Balance Evaluation System Test (Min... The present recommendations of measures, metrics, technology, and protocols build on previous consensus meetings of the International Stroke Recovery and Rehabilitation Alliance to guide the research ...

Standardized measurement of balance and mobility post-stroke: Consensus-based core recommendations from the third Stroke Recovery and Rehabilitation Roundtable.

Mobility is a key priority for stroke survivors. Worldwide consensus of standardized outcome instruments for measuring mobility recovery after stroke is an essential milestone to optimize the quality ... Using a standardized methodology, which involved convening of 13 worldwide experts in the field of mobility rehabilitation, consensus was established through an... Selected measures included the Fugl-Meyer Motor Assessment lower extremity subscale for motor function, the Trunk Impairment Scale for sitting balance, and the Mini Balance Evaluation System Test (Min... The present recommendations of measures, metrics, technology, and protocols build on previous consensus meetings of the International Stroke Recovery and Rehabilitation Alliance to guide the research ...

Investigating the role of interpersonal relationships on low-income SUD patients' recovery: a qualitative analysis of various stakeholders in New York State.

While positive impacts of recovery capital and social capital in facilitating substance use disorder (SUD) recovery is increasingly documented, research has shown that low-income and marginalized indi... Qualitative data were gathered through semi-structured interviews and analyzed employing thematic analysis. Participants included individuals with SUD (n=10), clinicians (n=12), and policy leaders (n=... Three themes emerged: 1) Patients' positive and negative interpersonal relationships with friends and family influenced decisions to seek treatment; 2) strong patient-provider relationships, often def... Our study underscores the importance of interpersonal relationships in SUD treatment-seeking and recovery and the need for positive interactions across the care continuum within broader social network...